**Background:** Demonstrating the cost-effectiveness of new treatments for multiple myeloma (MM) often relies on the extrapolation of overall survival (OS) trial data. This method can introduce uncertainty in long-term survival estimates if OS data are immature. as is often the case in newly diagnosed MM (NDMM). We explore the use of the relationship between minimal residual disease (... https://thecookiecountesses.shop/product-category/pens-and-markers/